

**The City of Yokohama Frankfurt Representative Office**

and

**Kihara memorial Yokohama Foundation for the  
Advancement of Life Science**

present



## **YOUR OPPORTUNITY TO MEET WITH HIGHLY INNOVATIVE JAPANESE BIOTECH COMPANIES AT BIO-EUROPE 2011**



A delegation of biotechnology companies from Yokohama will attend "BIO-Europe 2011 Düsseldorf".

They widely seek business partners and hope with eagerness that many groups will deal with them.

Yokohama-Kanagawa Bio-Businessnetwork (YK-Bionet), one of the leading clusters in biotechnology in Japan, are consisted of small and medium-

sized biotechnology enterprises implementing excellent research such as Diagnostic Antibodies, drug development derived ES/iPS cells, profiling glycan structure, DNA diagnostics or production of recombinant proteins..

In October/November 2011, the YK-Bionet delegation will have plenty of one to one business meetings with European companies at "BIO-Europe 2011 Düsseldorf", Europe's largest partnering conference, we seek collaboration partners for Business Development, Customers and Licensing Opportunities with leaders from biotechnology and pharmaceuticals along with exciting emerging companies.



### **SAVE THE DATE:**

From: 31 October 2011

To: 02 November 2011

### **WHERE:**

BIO-Europe 2011

CCD Congress Center Düsseldorf

Please contact us when the online partnering system opens

### **Organizer of the delegation:**

Kihara memorial Yokohama Foundation for the  
Advancement of Life Science



Kihara memorial Yokohama Foundation for the Advancement of Life Science: The foundation organizes joint research projects between universities, institutes and business enterprises in life science, and as a centre of "Life Science City Yokohama Project" promoted by the City of Yokohama, Kihara is contributing to advancement of life science and implementing vitalization and growth on local economy.

## PARTICIPATING COMPANIES:

Profile, products, business opportunities



**ReproCELL Inc.** was founded in 2003 based on the world-leading stem cell technologies developed by Kyoto University and Tokyo University. Since then ReproCELL has put a number of unprecedented original products into the market by collaborating closely with both of academic and industrial leaders in the field.

ReproCELL can offer a whole range of stem cell technologies including

- **Culture reagents** for human ES/iPS cells which realized establishment of the first human iPS cells by Professor Yamanaka in 2007
- World's first commercial **human iPS cell-derived cardiomyocytes / neurons / hepatocytes** to innovate research and drug development
- **Assay services** (e.g. QT prolongation assay) with ES/iPS cell-derived functional cells
- **Disease model generation** using human ES/iPS cell technology

[www.reprocell.com/en](http://www.reprocell.com/en)

[info\\_repro@reprocell.com](mailto:info_repro@reprocell.com)



**System Biotics** is a manufacturer expanding its business in full line-up supportive equipments of various researches. We are ready to customize along with customers' needs, including co-development or technology license-out. In particular our advantage, we have enormous know-how, tools

and other intellectual properties solving interface compatibility between hardware and software. These properties enable us to embed original software for methods of analysis or evaluation, developed by customers, into our hardware. Easy-type Automated ELISA device for sensing aging human skins, co-developing with Yokohama City University and Fancl, is near on the market.

Our intelligent bio instruments are built up using ActiveX components. Then you can control our instruments independently when you program your own computer programs with our ActiveX.

Otherwise our products line-up are Easy-type Automated Immuno Chromatography Line Pipetting Device, Easy-type Automated Ink-jet Pipetting Device, 8 Nozzles for Washing on MicroPlate Easy Flow & Stop only by one finger, Semi-Automated Washing on MicroPlate Easy Delivery & Suction only with Manual Valves, Automated Washing on MicroPlate Easy Delivery & Suction only with a Grip Switch, 12 Channel pipetting Device and Mini-Size Pipetting Device.

In this mission, we hope to contact researchers, manufacturers of research supporting equipment and off course, potential distributors of our products.

<http://www.systembiotics.com/framepageE11.html>

**RIKEN GENESIS** was established in 2007 as a RIKEN venture company to take over the genetic analysis technologies developed by Center for Genomic Medicine at RIKEN which acted as an international driving force for research of genomic medicine. Recent genomic research reveals the relationship between genes and diseases and the causes of drug side effects. Through its cutting-edge genetic analysis technologies with skilled staff and sophisticated instruments, RIKEN GENESIS contributes to making personalized medicine a reality and supporting a better Quality of Life.



RIKEN GENEIS provides cutting-edge genetic analysis service (genotyping and sequencing) to research institutes, companies, and medical institutes all over the world. RIKEN GENESIS supports the genomic research such as GWAS (Genome-wide Association Study) and pharmacogenomics (PGx) by its world-class quality and capacity that analyze tens of thousands samples per year. RIKEN GENESIS's laboratory is comply with Good Laboratory Practice (GLP), is accredited from the College of American Pathologists (CAP) as the first-ever laboratory in Japan for an independent genetic analysis facility, and is a certified service provider from Illumina Inc. (CSPPro).

On the top of genetic analysis service, RIKENGENESIS serves hospitals and clinical centers with its proprietary genetic analysis system and reagent kits. Our genetic analysis products includes tests of most FDA validated genetic markers, specially developed PGx tests for Warfarin, Nevirapine, and Carbamazepine, and somatic mutation analysis such for KRAS, BRAF, NRAS, EGFR, PI3K, and ABL.

RIKEN GENESIS complies with regulatory affairs in major countries: ISO13485, Marketing Authorization Holder and authorized Manufacturer of IVDs in Japan. Though those cutting-edge infrastructure, proprietary products, skilled staff, and experienced regulatory affairs, RIKEN GENESIS is ready for the companion drug development by the request of pharmaceutical companies.

<http://www.rikengenesi.jp/en/index.html>



**TagCyx Biotechnologies** is a research-based company devoted to the development of next generation platform technologies in the biotechnology arena, based on its unique, proprietary unnatural base pair systems. TagCyx's core technologies enable the site-specific incorporation of nucleotide analogs into DNA and RNA, and amino acid analogs into proteins.

TagCyx's technologies have great opportunities for broad applications. Using the unnatural base pair systems, multiple platforms are available not only for basic research, but also for diagnostics, therapeutics, and biometrics. TagCyx's mission is to develop and commercialize products and services through our technologies. TagCyx is committed to the continued development of novel applications and technologies.

TagCyx is seeking potential partners to develop nucleic acid-based therapeutics and PCR diagnostics using "unnatural base pair systems".

[http://www.tagcyx.com/index\\_en.html](http://www.tagcyx.com/index_en.html)

**GenoDive Pharma** is a venture business spun off from the Tokai University School of Medicine. It was established in 2002 based on the "Inoko Microsatellite technology" of Dr. Hidetoshi Inoko, former dean of the medical school.



Now, GenoDive Pharma is working on two main tasks, which are identification of disease genes and drug discovery. We have conducted genome-wide association study using microsatellite markers followed by fine mapping based on SNPs, and identified many candidate targets for drug discovery. This methodology can also be applied to identification of causative polymorphism of drug adverse-effects. Many HLA alleles are also associated with severe drug reactions such as Stevens-Johnson syndrome. In collaboration with Dr. Shiina in Tokai University, we have developed super high resolution HLA genotyping system at the eight-digit

level using high-throughput DNA sequencer to eliminate phase ambiguities. We can now serve the brand-new typing system as well as conventional Luminex method. GenoDive Pharma has own quality assurance system for supporting drug application.

In collaboration with Dr. Yoshihara in Tokai University, we also have been focusing on the development of revolutionary drugs, an antibody drug and peptide medicine to multidrug-resistant gram-negative bacteria including *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Escherichia coli*. We are putting power especially into peptide medicine. The company would like to hold meetings with medicine manufacturers for the purpose of joint development and license out focusing on the anti-gram-negative bacteria project and contracting business on the HLA genotyping.

<http://www.genodive.com/>

## VENUE:



### **CCD Congress Center Düsseldorf**

Stockumer Kirchstr. 61  
40474 Düsseldorf

## DATES:

### **19 September 2011**

Partnering opens  
Start requesting meetings

### **21 October 2011**

Deadline for meeting requests before first scheduling round

### **24 October 2011**

First round of partnering schedules available

### **31 October – 02 November 2011**

BIO-Europe 2011  
Pick up your updated meeting schedule on site at the partnering desk



### **Contacts in Europe:**

The City of Yokohama  
Frankfurt Representative Office

Mr. Hiroyuki Okamoto, Chief Representative  
FBC 18F, Mainzer Landstr. 46  
60325 Frankfurt am Main, Germany  
Tel: +49 69 2423 110 Fax: +49 69 2423 1115  
Email: [okamoto@yokohama-city.de](mailto:okamoto@yokohama-city.de)  
<http://www.yokohama-city.de>